MREO vs. PEPG, CRBP, ADCT, ANRO, ATAI, ORGO, NLTX, ANL, HRTX, and TERN
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include PepGen (PEPG), Corbus Pharmaceuticals (CRBP), ADC Therapeutics (ADCT), Alto Neuroscience (ANRO), Atai Life Sciences (ATAI), Organogenesis (ORGO), Neoleukin Therapeutics (NLTX), Adlai Nortye (ANL), Heron Therapeutics (HRTX), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical preparations" industry.
Mereo BioPharma Group (NASDAQ:MREO) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
Mereo BioPharma Group has higher revenue and earnings than PepGen.
Mereo BioPharma Group's return on equity of 0.00% beat PepGen's return on equity.
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 3.0% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 4.0% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Mereo BioPharma Group currently has a consensus price target of $6.50, indicating a potential upside of 151.94%. PepGen has a consensus price target of $24.67, indicating a potential upside of 114.49%. Given Mereo BioPharma Group's higher probable upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than PepGen.
Mereo BioPharma Group has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, PepGen has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 1 articles in the media. Mereo BioPharma Group's average media sentiment score of -0.14 beat PepGen's score of -0.37 indicating that Mereo BioPharma Group is being referred to more favorably in the media.
Mereo BioPharma Group received 20 more outperform votes than PepGen when rated by MarketBeat users. However, 85.71% of users gave PepGen an outperform vote while only 71.11% of users gave Mereo BioPharma Group an outperform vote.
Summary
Mereo BioPharma Group beats PepGen on 8 of the 11 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
